We are thrilled to announce the appointment of Dr. Maciej Trzaskowski, PhD as our new Chief Scientific Officer! His extensive background, including roles at King’s College London, QUT, and as Founder of InteliMagik, aligns perfectly with Ketim’s vision to transform mental health screening and therapeutic solutions. Stay tuned for what’s next as we push the boundaries of innovation together!

Ketim Therapeutics has achieved a significant breakthrough in maternal mental health research with the successful completion of a pilot study examining blood samples from the Queensland Family Cohort Study. In collaboration with the Australian Genome Research Facility, Ketim identified an 11-protein biomarker signature linked to postpartum depression (PPD) risk, out of over 5,400 proteins screened. This finding could enable the early prediction of PPD, offering a lifeline to mothers at risk. The next phase involves validating these results in an independent birth cohort, a process already underway, bringing Ketim closer to developing a reliable, non-invasive screening tool that could transform maternal healthcare.

Excerpt:

Ketim Therapeutics has partnered with Mater Research to drive groundbreaking research into predictive biomarkers for perinatal depression using data from the Queensland Family Cohort (QFC) study. This collaboration marks a significant advance in Ketim’s mission to revolutionise mental health diagnostics and early intervention strategies through cutting-edge biomarker research and AI technology. Perinatal depression, a condition affecting up to 1 in 5 women, poses serious risks for mothers and families. By identifying early biological signals of perinatal depression through blood-based biomarkers, Ketim’s innovative technology aims to provide clinicians with a powerful, early detection tool that enables personalised care and support. This strategic partnership with Mater Research, affiliated with the University of Queensland, strengthens Ketim’s efforts to bridge research and clinical application, ultimately setting a new standard for early diagnostic precision in maternal mental health.